Edwards Lifesciences sell-off may be buying opportunity, says Piper Jaffray

Piper Jaffray believes the sell-off in shares of Edwards Lifesciences following the company's lowered Q3 guidance could be a good buying opportunity for long-term investors. The firm lowered its price target for shares to $105 from $118, but maintains an Overweight rating on the name.